Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to ease psoriatic arthritis pain

NCT ID NCT07406035

Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 5 times

Summary

This study tests a new drug called TQH3906 for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 156 adults will receive either TQH3906, a placebo, or an existing drug (tofacitinib) for 12 weeks. The main goal is to see if TQH3906 improves joint symptoms better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TQH3906 capsules (a tyrosine kinase inhibitor)
What this could lead to
If successful, this could provide a new oral treatment option for people with active psoriatic arthritis, potentially reducing joint pain and swelling.
What could go wrong
This is an early Phase 2 trial with only 156 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sign a written Informed Consent Form, which must meet the following requirements * Be willing to participate in the study and able to sign the informed consent form; * Be willing and able to complete all study-specific procedures and visits; * PsA trial participant disease characteristics * Aged 18 to 70 years（inclusive）; * ii.diagnosed with PsA for at least 3 months prior to screening, and meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening; * Active arthritis at screening and at baseline (Day 1); * Has failed or was intolerant to at least one prior therapy; * If receiving a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD), trial participants must be on only one DMARD, which must have been administered for at least 3 months prior to screening, with a stable dose for at least 28 days prior to the first dose; * If using NSAIDs, the dose must have been stable for at least 14 days before the first dose; * If using oral corticosteroids, the dose must have been stable for at least 14 days before the first dose; * Topical treatments for plaque psoriasis must have remained stable for at least 14 days before the first dose; * Female participants of child-bearing potential shall agree to use effective contraception during the study and for 30 days following the last dose, and pregnancy tests at the screening and baseline visits shall be negative; male participants shall agree to use effective contraception during the study and for 30 days following the last dose. Exclusion Criteria: * Presence of conditions other than PsA: * Presence of non-plaque psoriasis (i.e., guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) at screening or first dose; * Presence of any other autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, etc.; * Presence of active (i.e., currently symptomatic) fibromyalgia; * Other Medical Conditions and Medical History: * Trial participants who are pregnant or breastfeeding; * Evidence of a serious illness/condition or unstable clinical condition, or localized active infection/infectious disease; * Any major surgery performed within 30 days prior to the first dose of study treatment, or any planned surgery during the study; * Cancer or a history of cancer or lymphoproliferative disease within the past 5 years; * New York Heart Association (NYHA) Class III or IV congestive heart failure, or any recent episode of heart failure resulting in NYHA Class III/IV symptoms; or a history of clinically significant ventricular arrhythmia or arrhythmia requiring continuous antiarrhythmic drug therapy; * Uncontrolled hypertension at screening or randomization; * History of thrombotic disease within 24 weeks prior to screening; viii. History of acute coronary syndrome and/or any major cerebrovascular disease within 24 weeks prior to screening; * Current or recent (within 3 months prior to randomization) gastrointestinal disease that may affect absorption of study treatment, including gastrointestinal surgery; * Severe blood loss (\> 500 mL) or blood transfusion within 4 weeks prior to randomization; * Inability to take oral medication; * Inability to undergo venipuncture and/or tolerate venous access; * History of substance abuse with inability to abstain or presence of a psychiatric disorder; * Any other medical, psychiatric, and/or social reason as determined by medical judgment; * Prior and concomitant medications: If the trial participant has a history of biologic use, the exclusion criteria specified in the protocol will apply; * Infection-related: * Active tuberculosis identified by chest radiography within 6 months prior to screening; trial participants with a negative chest radiography within 3 months prior to screening are eligible if they meet the protocol requirements; * Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection; or syphilis infection requiring treatment; * Abnormal physical examination or laboratory findings; * Other: * History of any major drug allergy; known allergy to any excipient of the investigational product; * Inability to comply with the trial protocol; * History of substance abuse with inability to abstain or presence of a psychiatric disorder; * Participation in another clinical trial and use of another investigational drug (other than for psoriatic arthritis) within 4 weeks prior to the first dose, based on the date of discontinuation from the previous trial; * Planned or previous allogeneic bone marrow transplantation or solid organ transplantation; * Any condition that, in the investigator's judgment, poses a serious risk to the safety of the trial participant or affects the participant's ability to complete the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    39 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Southwest Medical University

    RECRUITING

    Luzhou, Sichuan, 646000, China

  • Bao Ding NO.1 Central

    RECRUITING

    Baoding, Hebei, 071000, China

  • Bozhou People's Hospital

    RECRUITING

    Bozhou, Anhui, 236805, China

  • Deyang People's Hospital

    RECRUITING

    Deyang, Sichuan, 618199, China

  • Dongguan People's Hospital

    RECRUITING

    Dongguan, Guangdong, 523109, China

  • Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine

    RECRUITING

    Cangzhou, Hebei, 061000, China

  • Hospital of North Sichuan Medical College

    RECRUITING

    Nanchong, Sichuan, 637100, China

  • Jiangmen Central Hospital

    RECRUITING

    Jiangmen, Guangdong, 529030, China

  • Jiangsu Peopince Hospital

    RECRUITING

    Nanjing, Jiangsu, 210001, China

  • Jilin Provincial People's Hospital

    RECRUITING

    Changchun, Jilin, 130000, China

  • Kaifeng People's Hospital

    RECRUITING

    Kaifeng, Henan, 475000, China

  • Linfen Central Hospital

    RECRUITING

    Linfen, Shanxi, 041099, China

  • Luoyang Orthopedic-Traumatological Hospital Of Henan Province(Henan Provincial Orthopedic Hospital)

    RECRUITING

    Luoyang, Henan, 471002, China

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Ningbo Medical Center Li HuiLi Hospital

    RECRUITING

    Ningbo, Zhejiang, 315010, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

  • Pingxiang People's Hospital

    NOT_YET_RECRUITING

    Pingxiang, Jiangxi, 337000, China

  • Puyang Oilfield General Hospital

    RECRUITING

    Puyang, Henan, 457001, China

  • Shandong Provincial Hospital

    RECRUITING

    Jinan, Shandong, 250021, China

  • Shanghai Tenth People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201821, China

  • Shenzhen Second People's Hospital

    RECRUITING

    Shenzhen, Guangdong, 518035, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • Southwest Hospital, Third Military Medical University (Army Medical University)

    RECRUITING

    Chongqing, Chongqing Municipality, 400038, China

  • The Affiliated Hospital of Guizhou Medical University

    WITHDRAWN

    Guiyang, Guizhou, 550004, China

  • The Central Hospital of Shaoyang

    WITHDRAWN

    Shaoyang, Hunan, 422000, China

  • The First Affiliated Hospital of Henan University of CM

    WITHDRAWN

    Zhengzhou, Henan, 450003, China

  • The First Affiliated Hospital of Henan University of science and Technology

    NOT_YET_RECRUITING

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510400, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

  • The First Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130021, China

  • The Second Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, 530007, China

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215004, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510630, China

  • The second hospital of dalian medical university

    WITHDRAWN

    Dalian, Liaoning, 116000, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300120, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300120, China

  • Weifang People'S Hospital

    RECRUITING

    Weifang, Shandong, 261000, China

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410008, China

  • Xinjiang Uygur Autonomous Region People's Hospital

    WITHDRAWN

    Ürümqi, Xinjiang, 830001, China

  • Yancheng No.1 People's Hospital

    RECRUITING

    Yancheng, Jiangsu, 224000, China

  • Zhuzhou Central Hospital

    RECRUITING

    Zhuzhou, Hunan, 412000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.